Ureteral stent symptoms and associated infections: A biomaterials perspective

Nature Reviews Urology

Volumn 6, Issue 8, 2009, Pages 440-448

  Chew, Ben H ^a   Lange, Dirk ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BIOMATERIAL; KETOROLAC; LEVOFLOXACIN; LIDOCAINE; NARCOTIC ANALGESIC AGENT; OXYBUTYNIN; PACLITAXEL; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYMER; POLYPEPTIDE ANTIBIOTIC AGENT; TACHYPLESIN; TAMSULOSIN; TRICLOSAN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BIOCOMPATIBILITY; BIOFILM; BLADDER IRRITATION; CATHETER INFECTION; CLINICAL TRIAL; COMPRESSIVE STRENGTH; DEVICE INFECTION; DRUG BLOOD LEVEL; DRUG ELUTING STENT; DRUG INTERMITTENT THERAPY; DYSURIA; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FLANK PAIN; HEMATURIA; HUMAN; KLEBSIELLA PNEUMONIAE; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SURFACE PROPERTY; TENSILE STRENGTH; URETER OBSTRUCTION; URETER STENT; URETER STONE; URETER STRICTURE; URETEROSCOPY; URINARY TRACT INFECTION;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG-ELUTING STENTS; HUMANS; POSTOPERATIVE COMPLICATIONS; PROSTHESIS-RELATED INFECTIONS; STENTS; URETERAL DISEASES;

EID: 77949371028     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.124     Document Type: Review

References (83)

1. Lee, C., Kuskowski, M., Premoli, J., skemp, N. & Monga, M. randomized evaluation of ureteral stents using validated symptom questionnaire. J. Endourol. 19, 990-993 (2005).
2. rana, A. M. & sabooh, A. Management strategies and results for severely encrusted retained ureteral stents. J. Endourol. 21, 628-632 (2007).
3. Lojanapiwat, B. endourologic management of severely encrusted ureteral stents. J. Med. Assoc. Thai. 88, 1203-1206 (2005).
4. watterson, J. D. et al. Ureteroscopy and holmium:YAG laser lithotripsy: an emerging definitive management strategy for symptomatic ureteral calculi in pregnancy. Urology 60, 383-387 (2002).
5. Polat, F. et al. An uncommon application of shock wave lithotripsy: encrusted double pigtail ureteral stent. Int. Urol. Nephrol. 37, 231-233 (2005).
6. Aravantinos, e., Gravas, s., Karatzas, A. D., Tzortzis, v. & Melekos, M. Forgotten, encrusted ureteral stents: a challenging problem with an endourologic solution. J. Endourol. 20, 1045-1049 (2006).
7. Aron, M. et al. Forgotten ureteral stents causing renal failure: multimodal endourologic treatment. J. Endourol. 20, 423-428 (2006).
8. singh, v., srinivastava, A., Kapoor, r. & Kumar, A. Can the complicated forgotten indwelling ureteric stents be lethal? Int. Urol. Nephrol. 37, 541-546 (2005).
9. Marques, A. P., reis, r. L. & Hunt, J. A. The effect of starch-based biomaterials on leukocyte adhesion and activation in vitro. J. Mater. Sci. Mater. Med. 16, 1029-1043 (2005).
10. velard, F. et al. Polymorphonuclear neutrophil response to hydroxyapatite particles, implication in acute inflammatory reaction. Acta Biomater. 5, 1708-1715 (2009).
11. Joshi, H. B. et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J. Urol. 169, 1060-1064 (2003).
12. wang, C. J., Huang, s. w. & Chang, C. H. indications of stented uncomplicated ureteroscopic lithotripsy: a prospective randomized controlled study. Urol. Res. 37, 83-88 (2009).
13. Makarov, D. v., Trock, B. J., Allaf, M. e. & Matlaga, B. r. The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis. Urology 71, 796-800 (2008).
14. Lennon, G. M. et al. 'Firm' versus 'soft' double pigtail ureteric stents: a randomised blind comparative trial. Eur. Urol. 28, 1-5 (1995).
15. Joshi, H. B. et al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J. Urol. 174, 2303-2306 (2005).
16. Ho, C. H. et al. Determining the appropriate length of a double-pigtail ureteral stent by both stent configurations and related symptoms. J. Endourol. 22, 1427-1431 (2008).
17. Chew, B. H. et al. Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent comfort. J. Endourol. 21, 1069-1075 (2007).
18. Palmer, J. s. & Palmer, L. s. Determining the proper stent length to use in children: age plus 10. J. Urol. 178, 1566-1569 (2007).
19. rane, A. et al. Have stent-related symptoms anything to do with placement technique? J. Endourol. 15, 741-745 (2001).
20. Al-Kandari, A. M. et al. effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J. Endourol. 21, 698-702 (2007).
21. Jeon, s. s., Choi, Y. s. & Hong, J. H. Determination of ideal stent length for endourologic surgery. J. Endourol. 21, 906-910 (2007).
22. Pilcher, J. M. & Patel, U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin. Radiol. 57, 59-62 (2002).
23. Hruby, G. w., Ames, C. D., Yan, Y., Monga, M. & Landman, J. Correlation of ureteric length with anthropometric variables of surface body habitus. BJU Int. 99, 1119-1122 (2007).
24. wang, C. J., Huang, s. w. & Chang, C. H. effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol. Res. 37, 147-152 (2009).
25. Damiano, r. et al. effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J. Endourol. 22, 651-656 (2008).
26. Beddingfield, r. et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J. Urol. 181, 170-176 (2009).
27. Beiko, D. T. et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J. Endourol. 18, 723-730 (2004).
28. Chew, B. H., Davoudi, H., Li, J. & Denstedt, J. D. A Ketorolac-eluting ureteral stent to improve patient comfort: testing its safety profile in a porcine model [abstract #1838]. J. Urol. 181 (4 Suppl.), 663 (2009).
29. Lingeman, J. e., Denstedt, J. D., Preminger, G. M., Li, J. & Krambeck, A. e. The first drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a Ketorolacloaded ureteral stent [abstract #2003]. J. Urol. 181 (4 Suppl.), 725-726 (2009).
30. watterson, J. D., Cadieux, P. A., stickler, D., reid, G. & Denstedt, J. D. swarming of Proteus mirabilis over ureteral stents: a comparative assessment. J. Endourol. 17, 523-527 (2003).
31. Hendlin, K. et al. Ureteral stents: coil strength and durometer. Urology 68, 42-45 (2006).
32. Okeke, Z. & smith, A. D. Malignant ureteral obstruction: the case for plastic ureteral stents. J. Endourol. 22, 2101-2103 (2008).
33. rotariu, P. et al. Management of malignant extrinsic compression of the ureter by simultaneous placement of two ipsilateral ureteral stents. J. Endourol. 15, 979-983 (2001).
34. Pedro, r. N., Hendlin, K., Kriedberg, C. & Monga, M. wire-based ureteral stents: impact on tensile strength and compression. Urology 70, 1057-1059 (2007).
35. Hendlin, K., vedula, K., Horn, C. & Monga, M. In vitro evaluation of ureteral stent compression. Urology 67, 679-682 (2006).
36. Christman, M. s., L'esperance, J. O., Choe, C. H., stroup, s. P. & Auge, B. K. Analysis of ureteral stent compression force and its role in malignant obstruction. J. Urol. 181, 392-396 (2009).
37. Borin, J. F., Melamud, O. & Clayman, r. v. initial experience with full-length metal stent to relieve malignant ureteral obstruction. J. Endourol. 20, 300-304 (2006).
38. wah, T. M., irving, H. C. & Cartledge, J. initial experience with the resonance metallic stent for antegrade ureteric stenting. Cardiovasc. Intervent. Radiol. 30, 705-710 (2007).
39. Liatsikos, e. et al. Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur. Urol. doi:10.1016/j.eururo.2009.02.004.
40. Liatsikos, e. N., Kagadis, G. C., Barbalias, G. A. & siablis, D. Ureteral metal stents: a tale or a tool? J. Endourol. 19, 934-939 (2005).
41. Liatsikos, e. N. et al. Metal stents for the management of malignant ureteral obstruction. J. Endourol. 22, 2099-2100 (2008).
42. warren, J. w. Catheter-associated urinary tract infections. Int. J. Antimicrob. Agents 17, 299-303 (2001).
43. Kehinde, e. O. et al. Factors predisposing to urinary tract infection after J ureteral stent insertion. J. Urol. 167, 1334-1337 (2002).
44. reid, G., Denstedt, J. D., Kang, Y. s., Lam, D. & Nause, C. Microbial adhesion and biofilm formation on ureteral stents in vitro and in vivo. J. Urol. 148, 1592-1594 (1992).
45. Paz, A. et al. Febrile complications following insertion of 100 double-J ureteral stents. J. Endourol. 19, 147-150 (2005).
46. sharifi Aghdas, F., Akhavizadegan, H., Aryanpoor, A., inanloo, H. & Karbakhsh, M. Fever after percutaneous nephrolithotomy: contributing factors. Surg. Infect. (Larchmt) 7, 367-371 (2006).
47. Kehinde, e. O. et al. Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J. Endourol. 18, 891-896 (2004).
48. schierholz, J. M., Beuth, J. & Pulverer, G. silver coating of medical devices for catheterassociated infections? Am. J. Med. 107, 101-102 (1999).
49. Connell, i. et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl Acad. Sci. USA 93, 9827-9832 (1996).
50. santin, M., Motta, A., Denyer, s. P. & Cannas, M. effect of the urine conditioning film on ureteral stent encrustation and characterization of its protein composition. Biomaterials 20, 1245-1251 (1999).
51. van rooijen, J. J., voskamp, A. F., Kamerling, J. P. & vliegenthart, J. F. Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. Glycobiology 9, 21-30 (1999).
52. reinhart, H., Obedeanu, N., Merzbach, D. & sobel, J. D. effect of Tamm-Horsfall protein on chemoluminescence response of polymorphonuclear leukocytes to uropathogenic Escherichia coli. J. Infect. Dis. 164, 404-406 (1991).
53. Pak, J., Pu, Y., Zhang, Z. T., Hasty, D. L. & wu, X. r. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin ia and ib receptors. J. Biol. Chem. 276, 9924-9930 (2001).
54. schembri, M. A. & Klemm, P. Biofilm formation in a hydrodynamic environment by novel fimh variants and ramifications for virulence. Infect. Immun. 69, 1322-1328 (2001).
55. Nowicki, B., selvarangan, r. & Nowicki, s. Family of Escherichia coli Dr adhesins: decay-accelerating factor receptor recognition and invasiveness. J. Infect. Dis. 183 (Suppl. 1), s24-s27 (2001).
56. Nallapareddy, s. r., Qin, X., weinstock, G. M., Hook, M. & Murray, B. e. Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix proteins collagen type iv and laminin as well as collagen type i. Infect. Immun. 68, 5218-5224 (2000).
57. selvarangan, r. et al. interaction of Dr adhesin with collagen type iv is a critical step in Escherichia coli renal persistence. Infect. Immun. 72, 4827-4835 (2004).
58. sauer, K., Camper, A. K., ehrlich, G. D., Costerton, J. w. & Davies, D. G. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J. Bacteriol. 184, 1140-1154 (2002).
59. Makin, s. A. & Beveridge, T. J. The influence of A-band and B-band lipopolysaccharide on the surface characteristics and adhesion of Pseudomonas aeruginosa to surfaces. Microbiology 142, 299-307 (1996).
60. Atabek, A., Liu, Y., Pinzon-Arango, P. A. & Camesano, T. A. importance of LPs structure on protein interactions with Pseudomonas aeruginosa. Colloids Surf. B. Biointerfaces 67, 115-121 (2008).
61. wassall, M. A., santin, M., Peluso, G. & Denyer, s. P. Possible role of alpha-1-microglobulin in mediating bacterial attachment to model surfaces. J. Biomed. Mater. Res. 40, 365-370 (1998).
62. santin, M., wassall, M. A., Peluso, G. & Denyer, s. P. Adsorption of alpha-1-microglobulin from biological fluids onto polymer surfaces. Biomaterials 18, 823-827 (1997).
63. santin, M., Cannas, M., wassall, M. A. & Denyer, s. P. Adsorption of serum alpha-1-microglobulin onto biomaterials. J. Mater. Sci. Mater. Med. 9, 135-140 (1998).
64. Carnazza, s., satriano, C., Guglielmino, s. & Marletta, G. Fast exopolysaccharide secretion of Pseudomonas aeruginosa on polar polymer surfaces. J. Colloid Interface Sci. 289, 386-393 (2005).
65. van Merode, A. e., van der Mei, H. C., Busscher, H. J. & Krom, B. P. influence of culture heterogeneity in cell surface charge on adhesion and biofilm formation by Enterococcus faecalis. J. Bacteriol. 188, 2421-2426 (2006).
66. Downer, A., Morris, N., Feast, w. J. & stickler, D. Polymer surface properties and their effect on the adhesion of Proteus mirabilis. Proc. Inst. Mech. Eng. H 217, 279-289 (2003).
67. stickler, D. J. et al. Observations on the adherence of Proteus mirabilis onto polymer surfaces. J. Appl. Microbiol. 100, 1028-1033 (2006).
68. riedl, C. r., witkowski, M., Plas, e. & Pflueger, H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int. J. Antimicrob. Agents 19, 507-510 (2002).
69. Cauda, F., Cauda, v., Fiori, C., Onida, B. & Garrone, e. Heparin coating on ureteral double J stents prevents encrustations: an in vivo case study. J. Endourol. 22, 465-472 (2008).
70. Lange, D. et al. The interaction of uropathogens with the surfaces of urological stents utilizing different surface properties. J. Urol. (in press).
71. Abu-Lail, N. i. & Camesano, T. A. role of lipopolysaccharides in the adhesion, retention, and transport of Escherichia coli JM109. Environ. Sci. Technol. 37, 2173-2183 (2003).
72. shanks, r. M. et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect. Immun. 73, 4596-4606 (2005).
73. Zupkas, P., Parsons, C. L., Percival, C. & Monga, M. Pentosanpolysulfate coating of silicone reduces encrustation. J. Endourol. 14, 483-488 (2000).
74. Laube, N. et al. Coating with plasma-deposited functionalized diamond-like carbon to decrease encrustations on urological implants [German]. Urologe A 46, 1249-1251 (2007).
75. Chew, B. H., Cadieux, P. A., reid, G. & Denstedt, J. D. In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens. J. Endourol. 20, 949-958 (2006).
76. Cadieux, P. A. et al. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J. Urol. 175, 2331-2335 (2006).
77. Chew, B. et al. Uropathogen stimulated cytokine expression in bladder and kidney cell culture and the effects of triclosan [abstract #MP-2.05]. Canad. Urol. Assoc. J. 2, 257 (2008).
78. elwood, C. N. et al. Triclosan inhibits uropathogenic Escherichia coli-stimulated tumor necrosis factor-alpha secretion in T24 bladder cells in vitro. J. Endourol. 21, 1217-1222 (2007).
79. Liatsikos, e. N. et al. Application of paclitaxeleluting metal mesh stents within the pig ureter: an experimental study. Eur. Urol. 51, 217-223 (2007).
80. Minardi, D. et al. The antimicrobial peptide tachyplesin iii coated alone and in combination with intraperitoneal piperacillintazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model. Peptides 28, 2293-2298 (2007).
81. Orlando, F. et al. BMAP-28 improves the efficacy of vancomycin in rat models of Gram-positive cocci ureteral stent infection. Peptides 29, 1118-1123 (2008).
82. Tenke, P., Kovacs, B., Benko, r., Ashaber, D. & Nagy, e. Continuous versus intermittent levofloxacin treatment in complicated urinary tract infections caused by urinary obstruction temporarily relieved by foreign body insertion. Int. J. Antimicrob. Agents 28 (Suppl. 1), s82-s85 (2006).
83. Hadaschik, B. A. et al. investigation of a novel degradable ureteral stent in a porcine model. J. Urol. 180, 1161-1166 (2008).